November 7, 2026 - 11:52

Cardinal Health has updated its earnings forecast for fiscal 2027 after experiencing significant profit growth in its pharmaceutical and specialty segments during the first quarter. The company reported double-digit increases in these areas, contributing to overall positive financial results.
As a result of this strong performance, Cardinal Health now anticipates non-GAAP diluted earnings per share to fall between $12.80 and $13.00. This optimistic outlook reflects the company's confidence in its ongoing strategies and the robustness of its growth businesses.
Executives highlighted the importance of innovation and efficiency in driving these results, emphasizing the commitment to enhancing customer value and expanding market reach. The company's ability to navigate challenges in the healthcare landscape while capitalizing on emerging opportunities has positioned it well for future growth.
Investors and analysts will be closely monitoring Cardinal Health's progress as it continues to adapt to evolving market conditions and strive for sustained profitability.
November 6, 2026 - 20:03
U Power Limited Shares First Half Financial Results for 2026U Power Limited, known for its innovative electric vehicle battery-swapping solutions, has released its interim unaudited financial results for the first half of 2026. The company, which utilizes...
November 6, 2026 - 03:46
Hyperliquid Strategies Reports Strong Q1 EarningsHyperliquid Strategies is taking steps to become a futures commission merchant for U.S. clients. In its latest earnings call, the company announced a remarkable $621 million in net income for the...
November 5, 2026 - 18:54
Charleston County Leaders to Consider $3 Million for Land PreservationCharleston County leaders will be meeting Thursday to discuss a request for over $3 million in Greenbelt funding, which would go toward preserving and protecting land in Hollywood. This funding is...
November 5, 2026 - 18:37
Agenus Aims for Phase 3 Trial in Colon Cancer as Funding Depends on EnrollmentAgenus plans to start patient enrollment in the coming months for a Phase 3 trial of its investigational immunotherapy combination BOT/BAL aimed at treating early-stage colon cancer. During a...